Clinical Trials Directory

Trials / Completed

CompletedNCT00467259

Endometrial Safety Study of Transdermal Testosterone (300 Mcg/Day) in Naturally Postmenopausal Women

A Randomized, Double-Blind, Placebo-controlled, Multicenter, 52-week Study to Evaluate the Endometrial Safety of Transdermal Testosterone (300 Mcg/Day) in Naturally Postmenopausal Women With Hypoactive Sexual Desire Disorder.

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
1,271 (actual)
Sponsor
Warner Chilcott · Industry
Sex
Female
Age
45 Years – 70 Years
Healthy volunteers
Not accepted

Summary

This study is designed to evaluate the endometrial safety of a testosterone patch as treatment for low libido in naturally postmenopausal women.

Detailed description

Naturally postmenopausal women with hypoactive sexual desire disorder (HSDD) will be randomized into a 52-week, multicenter, double-blind (DB), parallel-group, placebo-controlled study. Patients will be stratified based on whether they use concomitant estrogen/progestin therapy and then randomized in a 4:1 ration to receive either testosterone transdermal system (300 mcg/day) or placebo. Patients using estrogen/progestin at the start of the study should maintain this therapy throughout the study; patients not using estrogen/progestin at the start of the study should not initiate estrogen/progestin therapy throughout the study. Endometrial biopsies and transvaginal ultrasounds will be collected/performed at screening and study exit for all patients. Safety will be assessed by adverse events, reports of vaginal bleeding, lipids, serum chemistry, and hematology. Physical exams, pap smears, and mammograms will be monitored.

Conditions

Interventions

TypeNameDescription
DRUGTestosterone Transdermal SystemTestosterone patch, 300 mcg/day, change patch twice a week for 52 weeks
DRUGPlacebo patchplacebo patch, changed twice a week for 52 weeks

Timeline

Start date
2007-04-01
Primary completion
2009-01-01
Completion
2009-01-01
First posted
2007-04-30
Last updated
2011-12-15
Results posted
2011-12-15

Locations

115 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00467259. Inclusion in this directory is not an endorsement.

Endometrial Safety Study of Transdermal Testosterone (300 Mcg/Day) in Naturally Postmenopausal Women (NCT00467259) · Clinical Trials Directory